The French company Valneva, which makes vaccines, has decided to close its facility in Nantes, France. This building is used for making vaccines and researching new ones. The company will now focus its work in Lyon, where it first started, and Vienna, where most of its research is already done. Valneva recently lowered its expected sales for 2025. In an email to Pharmaceutical Technology, a Valneva spokesperson said that 30 jobs will be lost because of this move. At the end of 2024, the company had 713 employees. The spokesperson also said that no research work will stop. All research will now be done at the company’s site in Vienna. This change comes after Valneva released its financial reports for the first nine months of 2025. Even though the company made more money, it lowered its expected sales for 2025. It now expects to sell between €155m ($179.7m) and €170m worth of products, down from its earlier target of €170m-€180m. One reason for this is that the US Food and Drug Administration (FDA) banned the company’s chikungunya vaccine, Ixchiq, because of safety concerns. This means the vaccine cannot be shipped or sold in the US. Valneva said this ban greatly affected its sales, especially for vaccines meant for travelers. The company said it has responded to the FDA and is waiting for more information. Ixchiq is one of three vaccines made by Valneva. The other two are Ixiaro/Jespect for Japanese encephalitis and Dukoral for cholera. On the same day the Nantes news was announced, Valneva shared full results from a study of its Lyme disease vaccine candidate. This vaccine is being developed with Pfizer. The results showed that the vaccine created a strong immune response and was safe for all age groups six months after a third booster dose. If the next phase of the study goes well, Pfizer plans to submit the vaccine for approval in the US and Europe in 2026. Valneva is part of a vaccine industry that is facing an uncertain future in the US due to regulatory changes. Several policy shifts and leadership changes have drawn criticism from scientists and public health experts. Analysts predict that the vaccine sector will become volatile under the Trump administration.